Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

CJC-1295 · dosing reference

What dose information exists for CJC-1295?

Two distinct molecules share this name. The published human trials used the DAC (albumin-binding) form; the non-DAC fragment sold as “Mod GRF 1-29” has no comparable published human dose data in this file.

Published human study doses

Human study

Intervention parameters reported in individual published human studies. Each study stays separate; parameters are never aggregated across studies.

Human studyTeichman et al., J Clin Endocrinol Metab (2006)
Population
Healthy adults aged 21–61
Route
Subcutaneous
Dose as published
Subcutaneous ascending single doses (first trial) and two or three weekly or biweekly doses (second trial); the paper reports the well-tolerated doses as 30 or 60 µg/kg
Frequency
Single ascending doses; weekly or biweekly in the repeat-dose trial
Duration
Trials lasting 28 and 49 days
Endpoint
Peak and AUC of GH and IGF-I

Clinical / professional references

Clinical ref.

Protocols published by identifiable professional, clinic or pharmacy sources, recorded with author/clinic, date accessed and context.

Clinical referencePeptide Protocols: Volume One

Emphasizes distinguishing short-acting Mod GRF 1-29 (100 mcg per injection paired with a GHRP) to preserve natural physiological GH pulsatility, contrasting with continuous GHRH exposure from DAC formulations which risks pituitary receptor desensitization.

William A. Seeds, M.D. (Seeds Scientific Research & Performance Institute) — Professional medical handbook on cellular medicine and growth hormone secretagogue signaling.

Community-reported ranges

Community

What people report discussing or doing in forums, on Reddit and in videos. Included only to show demand and reported practice — never as clinical evidence.

Community reportedhigh discussion volume

CJC-1295 DAC: typically discussed as roughly 1,000–2,000 mcg (1–2 mg) total per week (not per kg, and not daily), often split into one or two weekly administrations.

  • CJC-1295 DAC incorporates an albumin-binding Drug Affinity Complex extending its elimination half-life to roughly 6–8 days. Prior internet tables that cited '100–300 mcg/kg/day' made a catastrophic unit error that conflated fixed micrograms with per-kilogram daily dosing.
  • Therapept documents this distinction strictly for harm reduction and error correction; this is community reporting, not a clinical protocol.
Reddit r/Peptides · Peptide forums · Last checked 22 September 2026

Community reports describe what people say they are doing. They are not equivalent to clinical evidence, and discussion volume says nothing about whether a practice is safe, effective or even real.

Community reportedhigh discussion volume

CJC-1295 without DAC (Mod GRF 1-29): typically discussed as 100 mcg fixed amount per injection (not per kg), 1 to 3 times daily, almost always co-administered with ipamorelin.

  • Mod GRF 1-29 is a 29-amino acid fragment with a half-life of ~30 minutes designed to elicit acute pulsatile GH release rather than constant elevation.
Reddit r/Peptides · Peptide forums · Last checked 22 September 2026

Community reports describe what people say they are doing. They are not equivalent to clinical evidence, and discussion volume says nothing about whether a practice is safe, effective or even real.

Why community reports are shown at all

People search for dose information before they search for anything else in this sector. Where discussion is widespread, pretending it does not exist helps nobody. Therapept reports the discussion — its rough shape, how common it is, and where it happens — while keeping it visibly separate from every other kind of source. Community reports describe what people say they are doing. They are not equivalent to clinical evidence.

Last reviewed 22 September 2026 · Compiled by Therapept Editorial · How these records are built